Cyrus Harmon, Director at Olema Pharmaceuticals, Inc. (OLMA), sold 30,000 shares at $12.23 ($384K) on 2024-01-31, disclosed to the SEC on 2024-02-02.
Scheduled sale ($384k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.23 | 25,000 | $306K | 79.7% |
| 2 | $15.56 | 5,000 | $78K | 20.3% |
| Total | $12.79 avg | 30,000 | $384K | 100% |
| Filing → |
| OLMA | SELL | 2026-01-16 | $102K | — | Filing → |
| OLMA | SELL | 2025-12-29 | $164K | — | Filing → |
| OLMA | SELL | 2025-09-18 | $285K | — | Filing → |